Next-generation biologics through genomic recoding
Location: Canada, Ontario, Boston
Employees: 11-50
Phone: +1 617-903-8359
Total raised: $87.4M
Founded date: 2016
Investors 5
| Date | Name | Website |
| - | Innovation... | innovation... |
| - | Pillar VC | pillar.vc |
| - | Dreamers V... | dreamers.v... |
| - | Digitalis ... | digitalisv... |
| - | OS Fund | osfund.co |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 21.07.2024 | Series B | $60.3M | Atlas Vent... |
| 06.11.2021 | Series A | $25M | - |
| 28.09.2017 | Seed | $2.1M | - |
Mentions in press and media 14
| Date | Title | Description |
| 25.07.2024 | GRO Biosciences Secures $60 Million to Revolutionize Gout Treatment** ** | ** In the bustling world of biotechnology, innovation is the lifeblood. GRO Biosciences, or GRObio, has just taken a giant leap forward. The company recently announced the closing of an oversubscribed $60.3 million Series B financing round.... |
| 21.07.2024 | GRO Biosciences Closes $60.3M Series B Financing | GRO Biosciences, a Cambridge, MA-based biotechnology company leveraging synthetic biology, raised $60.3M in Series B funding. The round, which brought the total amount to more than $90M, was led by Atlas Venture and Access Biotechnology. Pr... |
| 19.07.2024 | GRO Biosciences: Protein Therapeutics Company Raises $60 Million In Series B | GRO Biosciences (GRObio), a biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of an oversubscribed $60.3 million Series B fin... |
| 19.07.2024 | GRO Biosciences Closes $60M Series B Financing Co-Led by Atlas Venture and Access Biotechnology | Proceeds to advance clinical development of lead program for gout, broaden the Company’s pipeline, and expand its genomically recoded organism platform BOSTON–(BUSINESS WIRE)–July 19, 2024– GRO Biosciences Inc. (“GRObio”), a biotechnology c... |
| 19.07.2024 | GRO Bio gathers $60M series B to take gout rival to Krystexxa into clinic | GRO Biosciences has ended the week with an extra $60.3 million in the bank, which the protein therapeutics-focused biotech will use to push its lead gout treatment into clinical trials. Gout occurs when high levels of uric acid in the blood... |
| 20.06.2023 | This Startup Is Rewriting The Language Of Life To Make Smart Biologics | Pearl Bio co-founders: Michael Jewett, Amy Cayne Schwartz, and Farren Isaacs.Pearl Bio. |
| 10.05.2022 | Pow.bio’s continuous fermentation technology might be the key to scaling up food production for a growing population | Fermentation, the process of breaking down sugars using the enzymes of microorganisms, is almost as old as civilization itself. The use of microbial cultures to preserve and improve the nutritional value of foods and produce alcoholic bever... |
| 09.12.2021 | GRO Biosciences Announces Appointment of Bruce Beutel, PhD to Board of Directors and J.P. Morgan Health Care Conference Week Activities | GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the appointment of Bruce Beutel, PhD ... |
| 06.11.2021 | GRO Biosciences Announces $25M Series A | BOSTON, MA, GRO Biosciences closed a Series A financing totaling $25 million, co-led by Leaps by Bayer and Redmile Group. >> Click here for more funding data on GRO Biosciences >> To export GRO Biosciences funding data to PD... |
| 03.11.2021 | GRO Biosciences Announces $25M Series A Financing Led by Leaps by Bayer and Redmile Group | – Company advancing DuraLogic™ and ProGly™ platform chemistries which are poised to deliver the long-awaited promises of protein therapeutics for patients with autoimmune and metabolic diseases – – Proceeds to support key GRO platform devel... |
Show more